Herantis at a glance
Herantis Pharma
A clinical-stage biotechnology company developing neurorestorative therapies aimed at slowing or stopping the progression of Parkinson’s disease. Listed on Nasdaq First North Growth Market Finland under the ticker HRTIS.
Significant market opportunity
Herantis targets the global Parkinson’s disease market, projected to reach approximately USD 13 billion by 2034, with the aim of delivering the first disease-modifying treatments for the disease.
HER-096
Herantis’ lead product, HER-096 is a CDNF-derived peptidomimetic targeting multiple Parkinson’s disease mechanisms, including proteostasis imbalance, mitochondrial dysfunction, and neuroinflammation through modulation of the unfolded protein response (UPR).
Our differentiated approach
HER-096 represents a differentiated approach to disease modification in Parkinson’s disease, with a unique mechanism of action, translational biomarker evidence, and the potential to broadly address key drivers of Parkinson’s pathology.
Encouraging clinical data
The HER-096 program is being developed as a potential disease-modifying therapy and is ready to advance into a randomized, signal-seeking Phase 2 proof-of-concept trial in early-stage Parkinson’s disease. Subcutaneously administered HER-096 has completed Phase 1 clinical development, demonstrating a favorable safety profile, efficient brain penetration, and biomarker evidence of biological activity.
Partnership-driven development strategy
Herantis aims to create value through strategic partnerships for late-stage clinical development and commercialization.